Abstract:Based on our hypothesis that epitope vaccine may be a new strategy to induce high levels of neutralization antibodies against HIV–1, we prepared multiple–epitope vaccines using three neutralizing epitopes (GPGRAFY, RILAVERYLKD and ELDKWA) of HIV–1 gp160, and characterized their immunogenicity. Peptide 1 [C–G–(ELDKWA–GPGRAFY)2–K] and peptide 2 (CG–GPGRAFY–ELDKWA–G–RILAVERYLKD) were synthesized and conjugated with carrier protein bovine serum albumin (BSA). After vaccination antibody responses to these immunogens were induced and evaluated by ELISA. The C–G–(ELDKWA–GPGRAFY)2–K–BSA (BSA: carrier protein) multiple–epitope vaccine induced a strong antibody response to the C–G–(ELDKWA–GPGRAFY)2–K peptide (antibody titer: 1:25,600) and C–(ELDKWAG)4 peptide (antibody titer: 1:12,800), but a weak antibody response to the C–(GPCGRAFY)4 peptide. The CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K–BSA (BSA: carrier protein) multiple–epitope vaccine also induced strong antibody response to the CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K peptide (antibody titer: 1:25,600) and C–(ELLDKWAG)4 peptide (antibody titer: 1:6,400), a very strong response to C–(RIVALVERYLKD–G)2–K peptide (dilution: 1:102,400), and a very weak response to the C–(GPGRAFY)4 peptide (dilution: 1:400) in mice. Both antisera induced by both multiple–epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind two control peptides. In comparison with both epitope vaccines, the rgp160 subunit vaccine could induce weak epitope–specific antibody response to these three epitopes on the three epitope peptides and V3, N–domain and C–domain peptides (dilution: 1:400–1:1,600). These results indicate that both multiple–epitope vaccines could induce high levels of antibodies to both neutralizing epitopes RILAVERYLKD and ELDKWA, while the GPGRAFY epitope on both vaccines appeared to have weak immunogenicity. Both multiple–epitope vaccines showed significant potency on inducing high levels of epitope–specific neutralization antibodies in comparison with rgp160 subunit vaccine.

Predefined spacers between epitopes on a recombinant epitope-peptide impacted epitope-specific antibody response.

Repeated Epitope In The Recombinant Epitope-Peptide Could Enhance Eldkwa-Epitope-Specific Antibody Response

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Recombinant Multi-Epitope Vaccine Induce Predefined Epitope-Specific Antibodies Against HIV-1

Epitope-Vaccine Induces High Levels of Eldkwa-Epitope-Specific Neutralizing Antibody

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

Induction of High Levels of Epitope-Specific Antibodies by Epitope/peptide Candidate Vaccines Against Human Immunodeficiency Virus Type-1 (HIV-1).

Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines Against HIV–1

Deletion of Fusion Peptide or Destabilization of Fusion Core of HIV Gp41 Enhances Antigenicity and Immunogenicity of 4E10 Epitope

ELNKWA-epitope Specific Antibodies Induced by Epitope-Vaccine Recognize ELDKWA- and Other Two Neutralizing-Resistant Mutated Epitopes on HIV-1 Gp41

Expression, Purification, and Renaturation of a Recombinant Peptide-Based HIV Vaccine in Escherichia Coli.

HIV Epitope-Peptides in Aluminum Adjuvant Induced High Levels of Epitope-Specific Antibodies.

Altering the Specificity of the Antibody Response to HIV Gp120 with a Glycoconjugate Antigen.

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Predefined GPGRAFY-Epitope-Specific Monoclonal Antibodies with Different Activities for Recognizing Native HIV-1 Gp120

A Simpler and More Cost-Effective Peptide Biosynthetic Method Using the Truncated GST As Carrier for Epitope Mapping.

Hiv-1 Gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad Hiv-1 Neutralizing Antibodies